Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med 2018; 379:122-137.

Published: 17th September 2018

Authors: Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Lang I et al.

Conclusion

This update of two large RCTs showed that the addition of ovarian suppression to tamoxifen improved disease-free and overall survival after eight years. The further addition of exemestane resulted in even higher rates of freedom from recurrence. Ovarian suppression did increase the frequency of adverse events.

Pubmed Link

Your comments

0 Comments